MedXY News - daratumumab

$Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention$

Hematology-OncologyBispecific Antibodiesdaratumumab

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

By MedXY|Dec 18, 2025

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra

daratumumab

Latest news

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial